Novartis Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Novartis key operating metrics including Phase III Trials Products (Biosimilars), environmental, and social and governance score (ESG).

Phase III Trials Products (Biosimilars)

100.0%

FY, 2021

Registration Phase Products (Pharmaceuticals)

60.0%

FY, 2021

Phase I/II Trials Products

100

6.5%

FY, 2022

Operating Metrics

Metrics	FY, 2020	FY, 2021	FY, 2022
Phase III Trials Products (Biosimilars)	1	2
Registration Phase Products (Pharmaceuticals)	5	2
Phase I/II Trials Products	118	107	100
Phase III Trials Products	44	54	44
Registration Phase Products	5	8	8
Phase I/II Trials Products (Oncology)	51	49
Phase III Trials Products (Oncology)	22	27
Phase I/II Trials Products (Pharmaceuticals)	67	58
Phase III Trials Products (Pharmaceuticals)	21	25
Registration Phase Products (Oncology)		6
Patients			10M

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub